MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial aims were being To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of several exploratory https://rufusd433rdo7.therainblog.com/profile